Next Article in Journal
Hesperidin Methyl Chalcone Reduces the Arthritis Caused by TiO2 in Mice: Targeting Inflammation, Oxidative Stress, Cytokine Production, and Nociceptor Sensory Neuron Activation
Previous Article in Journal
Anthocyanins in Plant Food: Current Status, Genetic Modification, and Future Perspectives
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inhibitory Effects of 2-Aminoethoxydiphenyl Borate (2-APB) on Three KV1 Channel Currents

1
Zhejiang Provincial Key Laboratory of Resources Protection and Innovation of Traditional Chinese Medicine, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China
2
The State Key Laboratory of Subtropical Silviculture, Zhejiang Agriculture and Forestry University, Hangzhou 311300, China
3
Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054, China
4
Zhejiang Key Laboratory for Laboratory Animal and Safety Research, Hangzhou Medical College, Hangzhou 311300, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2023, 28(2), 871; https://doi.org/10.3390/molecules28020871
Submission received: 21 December 2022 / Revised: 11 January 2023 / Accepted: 12 January 2023 / Published: 15 January 2023

Abstract

:
2-Aminoethoxydiphenyl borate (2-APB), a boron-containing compound, is a multitarget compound with potential as a drug precursor and exerts various effects in systems of the human body. Ion channels are among the reported targets of 2-APB. The effects of 2-APB on voltage-gated potassium channels (KV) have been reported, but the types of KV channels that 2-APB inhibits and the inhibitory mechanism remain unknown. In this paper, we discovered that 2-APB acted as an inhibitor of three representative human KV1 channels. 2-APB significantly blocked A-type Kv channel KV1.4 in a concentration-dependent manner, with an IC50 of 67.3 μM, while it inhibited the delayed outward rectifier channels KV1.2 and KV1.3, with IC50s of 310.4 μM and 454.9 μM, respectively. Further studies on KV1.4 showed that V549, T551, A553, and L554 at the cavity region and N-terminal played significant roles in 2-APB’s effects on the KV1.4 channel. The results also indicated the importance of fast inactivation gating in determining the different effects of 2-APB on three channels. Interestingly, a current facilitation phenomenon by a short prepulse after 2-APB application was discovered for the first time. The docked modeling revealed that 2-APB could form hydrogen bonds with different sites in the cavity region of three channels, and the inhibition constants showed a similar trend to the experimental results. These findings revealed new molecular targets of 2-APB and demonstrated that 2-APB’s effects on KV1 channels might be part of the reason for the diverse bioactivities of 2-APB in the human body and in animal models of human disease.

1. Introduction

Boron, often as boric acid, is a trace and necessary element for bone metabolism, inflammation attenuation, wound healing, modulating hormone levels, enhancing magnesium absorption, attenuating oxidative stress, and ameliorating cisplatin-induced peripheral neuropathy. 2-Aminoethoxydiphenyl borate (2-APB), a boron-containing compound, exerts effects on neurons, adaptive and innate immunity, and muscle cells, and it provides a cytoprotective effect against reactive oxygen. The molecular pharmacology of 2-APB reveals its complex actions through multiple targets including ion channels, transporters, and enzymes. 2-APB has the potential to act as both as a drug and as a precursor of drugs. Interest in 2-APB and its derivatives regarding the design of bioactive molecules keeps increasing in recent years [1,2].
The ion channel is the third-largest family of signaling molecules and the second-largest druggable target group. 2-APB has been shown to act as either a blocker or an activator for various ion channels and is thus extensively used as a modulator of different types of ion channels in many studies [2,3,4,5]. As for potassium channels, 2-APB potently inhibited KCa3.1 in a reversible manner under a whole-cell patch clamp (half maximal inhibition 14.2 μM) [6]. 2-APB was found to be an effective activator for all members of the TREK subfamily (hKCNK2, hKCNK4, and hKCNK10), with the highest efficacy in hKCNK10 [3]. The effects of 2-APB on voltage-gated potassium channels (KV) have also been reported. 2-APB at 100 μM reversibly inhibited both the transient and sustained voltage-activated potassium current of Limulus ventral photoreceptors during depolarizing steps [7]. 2-APB also inhibited the delayed rectifier K+ current (IK), with an IC50 of 120 μM in guinea pig arteriole cells [8]. However, the types of KV channels inhibited and the inhibitory mechanism remain unknown.
Voltage-gated potassium channels mainly respond in the repolarization of action potentials and participate in the regulation of resting potentials in non-excitable cells involved in many physiological processes [9]. KV1, the largest subfamily of KV channels, includes at least eight genes (KCNA1-8) that encode KV1.1–KV1.8 proteins. A KV1 channel is formed by four α-subunits encircling a central ion conduction pore. Like many other KV channels, each subunit of KV1 consists of six transmembrane segments (S1 to S6) with a membrane re-entering P-loop (loop of S5–S6). Functional KV1 channels are widely expressed throughout the nervous system and are found in peripheral tissues such as the heart, the vasculature, and the immune system [10,11]. Although KV1 channels are conserved in a protein sequence, they can be divided into two types by their current characteristics. KV1.4 is a typical transient A-type channel, while the other seven types, including KV1.2 and KV1.3, are delayed outward rectification channels [12]. In this study, we discovered that 2-APB could inhibit the two types of KV1 currents with different potencies, and we studied the potential inhibitory mechanism.

2. Results

2.1. 2-APB Effects on Three hKV1 Channel Currents

We investigated 2-APB’s effects on the KV1.2, KV1.3, and KV1.4 channel currents.
KV1.2 currents were evoked in stably transfected CHO cell lines by a 2000 ms pulse at 20 mV from a holding potential at −80 mV (Figure 1A). Cumulative 2-APB concentrations (10, 30, 100, 300, and 1000 μM) were perfused directly to the cells by gravity. Data were obtained once the responses to 2-APB reached a steady state. The maximal current amplitudes were measured at the end of pulses. The percentage inhibitions by 10, 30, 100, 300, and 1000 μM 2-APB were 3.5 ± 1.2%, 12.8 ± 2.3%, 22.9 ± 2.7%, 43.4 ± 2.6%, and 77.8 ± 1.0%, respectively (n = 4; Figure 1B,C). The IC50 value was 310.4 ± 29.4 μM (n = 9). To assess the effect of 2-APB on the current–voltage (I-V) relationship, we constructed I-V curves with and without 2-APB in the bath (100 μM). 2-APB made the I-V curves shift to the right (Figure 1D).
KV1.3 currents were evoked by a 2000 ms length and +40 mV pulse from a holding potential at −80 mV. 2-APB conspicuously blocked KV1.3 currents (Figure 2A). Furthermore, 10, 30, 100, 300, and 1000 μM 2-APB was cumulatively perfused directly onto the cells, and it inhibited peak amplitudes by 7.2 ± 1.7%, 16.6 ± 2.9%, 25.3 ± 5.2%, 36.9 ± 4.2%, and 71.4 ± 5.8%, respectively (n = 6) (Figure 2B,C). The IC50 value was 454.9 ± 120.9 μM (n = 7). The I-V relationship curves before and after 2-APB application (100 μM) showed that the voltage dependence of peak currents apparently shifted (Figure 2D).
The concentration–response curves of KV1.2 and KV1.3 did not seem sigmoidal due to the responses not reaching the maximum yet.
KV1.4 currents were elicited with a voltage step (500 ms duration) to −10 mV from a holding potential of −80 mV. The currents evoked by this voltage-clamp protocol were transient A-type K+ currents that decayed rapidly. The percentage inhibitions by 10, 30, 100, 300, and 1000 μM 2-APB were 16.9 ± 1.6%, 30.3 ± 3.5%, 56.8 ± 2.7%, 77.9 ± 3.0%, and 93.8 ± 1.7%, respectively (n = 6) (Figure 3A–C). The IC50 value and Hill coefficient were 67.3 ± 5.32 μM (n = 6) and 1.59 ± 0.13, respectively. The I-V relationship studies showed that Kv1.4 currents were elicited by voltage pulses more positive than −40 mV, and the current amplitude increased linearly with further depolarization. The presence of 2-APB reduced the current amplitude over the entire voltage range, which activated the currents (Figure 3D).

2.2. Characteristics of the Inhibition of 2-APB on Kv1.4

To understand the potential inhibition mechanisms of 2-APB, we further investigated the 2-APB effect on KV1.4 since 2-APB was the most potent in inhibiting Kv1.4 among three KV1 channels. A two-pulse protocol (Figure 4A) was set to examine the recovery of the inactivation. Currents were evoked by the same amplitude, a 40 mV prepulse, and a test pulse from a holding potential at −80 mV. The interval between these two pulses was varied, and both peak currents evoked from the test pulse (I2) and the prepulse (I1) were recorded. The ratio of I2/I1 was plotted against the intervals and fitted by a single exponential. The time constant was 683.0 ± 80.5 ms and 624.2 ± 78.8 ms before and after 2-APB (100 μM) application (n = 5, p > 0.05) (Figure 4B). These data indicate that 2-APB had no effects on the recovery of the inactivation.
The effects on the onset of inactivation by 2-APB were also investigated. A two-pulse protocol (Figure 4A) was used. Currents were evoked by the same amplitude, a 40 mV prepulse, and a test pulse from a holding potential at −80 mV. The duration of the prepulse was varied, while the interval between these two pulses was fixed at 20 ms. Both peak currents evoked from the test pulse (I2) and the prepulse (I1) were recorded. The ratio of I2/I1 was plotted against the intervals and fitted by a single exponential. The onset of slow inactivation was measured by a prepulse duration from 32 ms to 2048 ms. The time constant was 74.5 ± 11.5 ms and 67.0 ± 8.2 ms before and after 2-APB (100 μM) application (n = 4, p > 0.05) (Figure 4D). The onset of fast inactivation was measured by a prepulse duration from 2 ms to 120 ms. However, the fit started at 8 ms. The time constancy was 36.2 ± 2.1 ms before and was 32.9 ± 0.9 ms after 2-APB (100 μM) application (n = 5, p > 0.05) (Figure 4C). These findings show that 2-APB had no effects on the onset of inactivation.
Figure 4C illustrates that the 2 ms length prepulse facilitated currents evoked by the test pulse. The facilitation of the amplitudes of currents (I2/I1) was 1.21 ± 0.03 vs. 2.80 ± 0.32 before and after 2-APB application (n = 5). It seemed like the facilitation was more than doubled after 2-APB application. However, it was actually because 2-APB suppressed the currents of the prepulse (I1) more than those of the test pulse (I2, Figure 5A,B). At this stage, the kinetics of the activation of the current were well fitted by the Boltzmann equation rather than a single exponential (Figure 5C). The average time to activate half of the maximal current was delayed by 0.6 ± 0.15 ms by 30 μM 2-APB (p < 0.01, n = 10) (Figure 5D). Meanwhile, the slope, which measured the speed of the activation, was also significantly slowed (p < 0.01, n = 10). It was 0.34 ± 0.12 pA/ms with 30 μM 2-APB, compared to 0.24 ± 0.02 pA/ms without 2-APB (Figure 5D). The data suggested that 2-APB delayed the KV1.4 activation at a 2 ms length of the prepulse.

2.3. Effects of 2-APB on Mutation hKv1.4 Channels

2.3.1. Mutations at the Pore Region

Considering that 2-APB exerts a much higher potency against KV1.4 channel currents, we further studied its inhibitory mechanism. Most known small-molecule inhibitors of KV channels bind a water-filled cavity below the selectivity filter that is formed by residues located at the base of the selectivity filter and by pore-lining amino acids of the inner (S6) helices [13]. We hypothesized that 2-APB might have a specific interaction site(s) on the KV1.4 channel and that the 2-APB interaction site(s) with the KV1.4 channel might locate in the channel cavity region. To identify the site(s), we conducted alanine scanning by making a series of site mutations, except for the A553 site that was mutated to A553V, in the channel cavity region (G548A, V549A, L550A, T551A, I552A, A553V, L554A, P555A, V556A, P557A, V558A, I559A, V560A). These mutations were transiently expressed in CHO cell lines. Despite some of these mutations having no currents or too few currents elicited for analysis, 100 μM 2-APB was used for studying the mutations of measurable currents. We found that four mutations (V549A, T551A, A553V, and L554A) significantly attenuated the 2-APB inhibition of the KV1.4 channel currents (Figure 6), whereas the other mutations had no significant effects (Table 1). This indicated that 2-APB might regulate KV1.4 channel activity through interactions with the four residues.

2.3.2. N-Terminal Truncation

KV1.4, as a typical A-type channel, has the fastest kinetic inactivation among KV1s, and 2-APB also has the strongest inhibition on KV1.4. It is interesting to investigate whether there is an impact on the inhibition of 2-APB if the fast inactivation is removed. Because the N-terminal of KV1.4 serves as the “ball” to deliver the fast inactivation by blocking the path of ions at the bundle cross of the S6 region [14], 1–61 amino acids at the N-terminal were removed to make a truncation mutation. Compared with the other mutations, the N-terminal-removed mutation was the least inhibited by 2-APB. Furthermore, 10, 30, 100, 300, and 1000 μM 2-APB inhibited peak amplitudes of KV1.4 currents by 1.5 ± 1.7%, 9.0 ± 0.9%, 23.1 ± 2.5%, 49.1 ± 2.9%, and 77.1 ± 3.8%, respectively (n = 5–6) (Figure 7). The IC50 value was 310.4 ± 16.6 μM (n = 6).
As the KV1.4 channels do not inactivate yet at 2 ms (Figure 5A,B), the activation delay is more probably correlated with the fast inactivation. Thus, the onset of the inactivation of the N-terminal truncation mutation was investigated. Since the N-terminal truncation mutation has lost inactivation, there was no clear inactivation detected in the first 32 ms (Figure 8A). Clear facilitation was discovered at at least 2, 4, and 8 ms with or without 2-APB. The facilitation of current amplitudes (I2/I1) at a 2 ms length prepulse was 2.23 ± 0.32 vs. 4.68 ± 0.69 before and after 30 μM 2-APB application (p < 0.05, n = 4) (Figure 8B). Similar to the effect on WT, the facilitation was more than doubled after 2-APB application. The average time needed to activate half of the maximal current was delayed by 0.4 ± 0.09 ms by 30 μM 2-APB (p < 0.05, n = 4). Meanwhile, the slope was 0.33 ± 0.02 pA/ms with 30 μM 2-APB, compared to 0.42 ± 0.07 pA/ms without 2-APB (n = 4, p > 0.05) (Figure 9).
The data suggested that the truncation of N-terminal reduced the 2-APB inhibition on KV1.4 channels but does not affect the short prepulse facilitation.

2.4. Docking of the Interactions between 2-APB and Three Channels

To further examine the possible interaction at the atomic level between the ligand 2-APB and hKV1.3 and hKV1.4 and the template structure of rKV1.2 channels, homology modeling of hKV1.3 and hKV1.4 and molecular docking of protein–ligands complexes were carried out. The sequence of the central pore of hKV1.3 and hKV1.4 was aligned with that of rKV1.2 according to the previous studies [15,16,17]. The hKV1.3, hKV1.4, and rKV1.2 share a ~90% sequence identity in the pore domain. Hence, using a Swiss-model workspace, we constructed a reliable 3D structure of hKV1.3 and hKV1.4 composed of S5, S6, and P-loop according to the crystal structure of rKV1.2. The quality of the refined models was then evaluated by the Ramachandran plot, which suggests that the Phi/Psi angles of most residues (~90%) are within the reasonable ranges. The flexible docking protocol was carried out to explore the molecular basis of the interaction between rKV1.2, hKV1.3, and hKV1.4 and 2-APB. Based on the docking analysis, the phenolic hydroxyl group of 2-APB showed an interaction with T401 (KV1.2 (2A79)), A473 (KV1.3 model), and V549 (KV1.4 model), respectively (Figure 10, Figure 11 and Figure 12). The best binding poses were chosen based on the binding energy score, the inhibition constant, the VDW_HB desolv_energy, and the ligand efficiency, and the surrounding residues of ligands may have an essential impact on the binding affinity between hKV1.4 and 2-APB. According to the computational docking results, the superposition of the binding structures for the inspected ligand is shown in Figure 10, Figure 11 and Figure 12. The inhibition constants (Ki) predicted were 218.87 μM, 350.52 μM, and 118.52 μM for rKV1.2, hKV1.3, and hKV1.4, respectively (Table 2). This shows a similar trend with the experimental data.

3. Discussion

Our study showed that 2-APB could significantly block three representative human KV1 channels. The most potent inhibition against A-type KV1.4 currents and a relatively weaker inhibition against two delayed outward rectifier channels were discovered. The mutations V549A, T551A, A553V, L554A, and N-terminal removal significantly attenuated 2-APB’s effects on KV1.4 channel currents. 2-APB did not affect the onset and recovery of KV1.4 inactivation but significantly slowed the initial activation kinetics of the channels. The importance of fast inactivation gating in determining the different 2-APB effects on the two types of channels was revealed. Interestingly, a current facilitation phenomenon by short prepulses was discovered for the first time.
Functional KV1 channels not only exist throughout both central and peripheral nervous systems but can also be expressed in peripheral tissues, including the cardiovascular and the immune system. Among them, KV1.2 is mostly in the central nervous system, and KV1.3 is more prominent in peripheral tissues. KV1.4, an A-type KV channel, is widely distributed in excitable cells of mammalian tissues and exists in the cardiac ventricular endocardium [18,19]. The inhibitory effects of 2-APB on three channels can be used to explain the effects of 2-APB on the human body and animal models of human disease. Inhibition on KV1.3 ought to be a reason for modulating adaptive and innate immunity by 2-APB, because KV1.3, as a drug target for autoimmune diseases, widely exists in immune cells. Inhibition on KV1.2 and KV1.4 should play a role in 2-APB’s effects on neurons, smooth muscle cells, and cardiomyocytes [2]. Inhibition on both the transient and sustained voltage-activated potassium current of Limulus ventral photoreceptors comprising a delayed outward rectifier K+ current and a rapidly inactivating conductance could also result from 2-APB’s effects on Kv1 channels [7].
2-APB showed the most potent effects on KV1.4 among three channels. Previous studies showed that 2-APB’s inhibitory effects on KV channels of guinea pig arteriole cells were more marked on the fast component than they were on the slow component [8]. Our results could provide an explanation.
Among the antagonists of KV1.4 channels, 2-APB, with an IC50 of 67.3 μM, is comparable to the effects of fluoxetine and La3+, and its inhibition is 4 and 100 times more potent than 4-aminopyridine and TEA, respectively [18]. The data indicated that the inhibitory potential of 2-APB is quite considerable. 2-APB has been widely used as a tool in many studies. It is worth noticing that 2-APB has also been used in several systems (e.g., rat dorsal root ganglia) that endogenously express KV1 as their major potassium background channels [20]. We think that any application of 2-APB over 10 μM at cellular levels should take into consideration the potential inhibition of KV1.4.
The V549A, T551A, A553V, and L554A mutations significantly attenuate 2-APB’s effects on KV1.4, and these four sites were conserved with KV1.2 (V399, T401, A403, L404) and KV1.3 (V469, T471, A473, L474) channels. It is reasonable to speculate that these sites might also play a key role in the inhibition of KV1.2 and KV1.3 by 2-APB. The variable IC50s in KV1.2 and KV1.3 indicated that other diverse regions or sites of these channels might be involved in the interaction between 2-APB and channels.
Fast inactivation is the characteristic of KV1.4 that distinguishes it from other KV1.x channels [21]. N-terminal removal will disrupt the fast inactivation of the channel. Our data of the N-terminal deleted channel showed the weakest inhibition by 2-APB, suggesting that the fast inactivation plays a vital role in the inhibition of 2-APB. Interestingly, N-terminal truncation caused the IC50 on KV1.4 to be nearly the same as that of KV1.2. Moreover, A553V mutation also disrupted the fast inactivation kinetics (Figure 6C) and mostly significantly attenuated 2-APB inhibition, which is consistent with the N-terminal truncation data. These findings provide additional evidence on the key role of the fast inactivation gate in the 2-APB effects on KV1.4. Considering that fast inactivation is the major difference between KV1.4 and the other KV1 channels, the fast inactivation characteristic of KV1.4 might determine the different inhibitory potencies of 2-APB against KV1.4 and the other two KV1channels.
Our data showed that 2-APB delayed the kinetic activation of KV1.4 when the prepulse length was 2 ms. The N-terminal truncated mutation altered neither this effect nor the amount of time delayed. We do not know whether other KV1.4 inhibitors have the same effect, or, in other words, whether this effect is 2-APB-specific. We suspect that 2-APB might have a direct impact on the channel opening, but further evidence is needed.
In the docking analysis, 2-APB had an interaction with V549 and did not bind with the other three key residues in the KV1.4 channel. 2-APB could also interact with T401 in Kv1.2 and A473 in KV1.3, which are conserved with T551 and A553 of the KV1.4 channel. The docking predictions were consistent with the inhibitory effects on three channels by 2-APB.

4. Materials and Methods

4.1. Materials

2-APB was purchased from Sigma (San Diego, CA, USA). The cDNAs for the human K+ channels KV1.2(NM_004974.4), KV1.3(NM_002232.5), and KV1.4 (NM_002233.4) were bought from OriGene Technologies (Rockville, MD, USA), subcloned into pcDNA3.1(neo+), and stably transfected into CHO cells, which were used to determine the IC50s of 2-APB in different channels.

4.2. Site-Directed and N-Terminal Truncation Mutations of KV1.4

Mutation PCR was performed with primers synthesized by Sangon biotech (Shanghai, China) using the KOD DNA polymerase (TOYOBO, Osaka, Japan). PCR products were digested by the DpnI restriction enzyme (TAKARA, Dalian, China), purified, and transformed into DH5α E. coli competent cells. Additionally, 1–61 amino acids were deleted for N-terminal truncation mutation. After sequencing, plasmids with the desired mutations were extracted and transiently transfected into Chinese hamster ovary (CHO) cells using Lipofectamine™ 2000.

4.3. Data Recording

CHO cells with KV1.2, 1.3, or 1.4 stably expressed were routinely cultured in the solution with 10% fetal bovine serum (FBS), 1% P/S (100U Penicillin and 0.1 mg/mL streptomycin), and 100 μg/mL G418. Cells not connected with other cells were voltage-clamped using the PC505B (Warner Instrument Corporation) patch clamp amplifier in the whole-cell configuration. Electrodes ranged from 2 to 3 MΩ in resistance. The voltage clamp data were filtered at 2 kHz and digitized at 100 or 150 ms/point. Voltage protocols were generated and analyzed by Clampex and Clampfit patch clamp software (Version 10.4, Axon Instruments). The recordings from cells were carried out at room temperature (25 ± 1 °C) [22].

4.4. Statistical Analysis

Electrophysiological data were analyzed by Clampfit software (Version 10.4, Axon Instruments) and Origin 8.0 (OriginLab Corporation, Northampton, MA, USA). All data were expressed as the mean ± S.E.M using Student’s t-tests with statistical significance (p < 0.05). The IC50 value was obtained by fitting the concentration-dependent data to the following Hill equation: I (%) = 1/{1 + (IC50/[D])n}. In the equation, I% is the percentage inhibition of current amplitudes; IC50 is the concentration of the half-maximal inhibition; [D] is the concentration of a compound; and n is the Hill coefficient.

4.5. Homology Modeling

The pore region sequences of hKV1.3 and hKV1.4 were retrieved from the Uniprot database (accession number: hKV1.3—P22001, hKV1.4—P22459), and multiple sequence alignment was carried out with the sequence of rat KV1.2. Since the crystal structure of the human voltage-gated potassium channels KV1.3 and KV1.4 has not yet been determined, the homology model of both channels was constructed by the Swiss-model based on the crystal structure of the rat KV1.2 channel (PDB entry: 2A79) [14,23]. The residues Met288 to Thr421, forming the S5 pore helix and S6 in rat KV1.2, correspond to the region from Met358 to Thr491 in hKV1.3, and Met438 to Thr571 in hKV1.4 was selected as the template for homology modeling. The sequence identity of these regions between the rat KV1.2, hKV1.3, and hKV1.4 was ~90%, which can enable us to construct a reliable homology model based on the high-resolution crystal structure of rat KV1.2. As the crystal structure of rat KV1.2 contains only one subunit, the transformation matrices of the structural coordinate file were employed to generate the missing subunits of rat KV1.2, creating the fourfold symmetry required to build the hKV1.3 and hKV1.4 channel homo-tetramer. The Ramachandran plot further assessed the quality of the refined model.

4.6. Induced Fit Docking

The compound 2-APB, the modeled target proteins hKV1.3 and hKV1.4, and the template structure of rat KV1.2 were used in the molecular docking analysis by the AutoDock tools (ADT) with the MGL Tools v1.5.6rc3 program [24]. All three target protein molecules were prepared by the Python Molecule Viewer (PMV); after repairing the missing atoms, the polar hydrogen atoms and Gasteiger charges were added into the protein structures. The active binding sites were selected at the central cavity of the pore region of hKV1.3 and hKV1.4 in each of the four subunits and were considered as flexible according to the previous study [25]; the rest of the target protein sites were treated as a rigid body. The parameter library was loaded for the ligand molecule 2-APB, and the atoms were also considered flexible. The grid map was constructed based on the ligand atom types with a default grid spacing of 0.375 A° in the box size of 90 × 90 × 90. After the grid map calculation, the target proteins and the ligand molecule were induced for docking analysis. The default genetic algorithm parameters with the addition of AutoDock 4.2 parameters were used for building 27,000 generations with a population size of 150 individuals. The docking conformations were calculated by the Lamarckian genetic algorithm (LGA) [26]. Finally, the least scored conformation was evaluated and picked for the ligand-receptor docking analysis; the interaction images were developed by PyMOL.

5. Conclusions

In conclusion, this study demonstrated that 2-APB could significantly block three representative human KV1 channels. Moreover, the potential inhibitory mechanism was also investigated. Therefore, 2-APB’s effects on KV1 channels might be part of the reason for the diverse bioactivities of 2-APB in the human body and in animal models of human disease. In other words, our study revealed new targets of 2-APB at the molecular level. More comprehensive research is needed to understand the inhibitory mechanism in more detail and more 2-APB effects on other channels.

Author Contributions

W.Z. and L.P. conducted most of the experiments; A.S. conducted the molecular modeling and docking analysis; J.X. was mainly involved in the cell culture and some electrophysiology experiments; L.W. was mainly involved in the electrophysiology experiments; X.K. and Y.C. designed all the experiments, gave the instructions, and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work received funding from the Scientific Research Foundation of Zhejiang A & F University (2013FR032 to Yuan Chen, 2016FR027 to Lanying Pan, 2019FR027 to Wei Zhao), and the Zhejiang Provincial Natural Science Foundation (LY20C040001 to Lanying Pan, LGF18H280002 and LBY22H270002 to Wei Zhao).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to acknowledge Zhejiang A & F University and Zhejiang Provincial Natural Science Foundation for supporting this work.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compound 2-APB are available from the authors.

References

  1. Eroglu, E.; Unel, C.C.; Harmanci, N.; Erol, K.; Ari, N.S.; Ozatik, O. 2-Aminoethoxydiphenyl borate ameliorates functional and structural abnormalities in cisplatin-induced peripheral neuropathy. J. Trace Elem. Med. Biol. 2022, 70, 126909. [Google Scholar] [CrossRef] [PubMed]
  2. Rosalez, M.N.; Estevez-Fregoso, E.; Alatorre, A.; Antonio, A.G.; Marvin, A.S.U. 2-aminoethyldiphenyl borinate: A multitarget compound with potential as a drug precursor. Curr. Mol. Pharmacol. 2020, 13, 57–75. [Google Scholar] [CrossRef] [PubMed]
  3. Beltrán, L.; Beltrán, M.; Aguado, A.; Gisselmann, G.; Hatt, H. 2-Aminoethoxydiphenyl borate activates the mechanically gated human KCNK channels KCNK2 (TREK-1), KCNK 4 (TRAAK), and KCNK 10 (TREK-2). Front. Pharmacol. 2013, 4, 63. [Google Scholar] [CrossRef] [Green Version]
  4. Maruyama, T.; Kanaji, T.; Nakade, S.; Kanno, T.; Mikoshiba, K. 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. J. Biochem. 1997, 122, 498–505. [Google Scholar] [CrossRef]
  5. Zhuo, R.G.; Liu, X.Y.; Zhang, S.Z.; Wei, X.L.; Zheng, J.Q.; Xu, J.P.; Ma, X.Y. Insights into the stimulatory mechanism of 2-aminoethoxydiphenyl borate on TREK-2 potassium channel. Neuroscience 2015, 300, 85–93. [Google Scholar] [CrossRef] [PubMed]
  6. Littlechild, R.; Zaidman, N.; Khodaverdi, D.; Mason, M.J. Inhibition of KCa3.1 by depolarisation and 2-aminoethoxydiphenyl borate (2-APB) during Ca2+ release activated Ca2+ (CRAC) entry in human erythroleukemia (HEL) cells: Implications for the interpretation of 2-APB inhibition of CRAC entry. Cell Calcium 2015, 57, 76–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Wang, Y.; Deshpande, M.; Payne, R. 2-Aminoethoxydiphenyl borate inhibits phototransduction and blocks voltage-gated potassium channels in Limulus ventral photoreceptors. Cell Calcium 2002, 32, 209–216. [Google Scholar] [CrossRef]
  8. Ma, K.T.; Guan, B.C.; Yang, Y.Q.; Nuttall, A.L.; Jiang, Z.G. 2-Aminoethoxydiphenyl borate blocks electrical coupling and inhibits voltage-gated K+ channels in guinea pig arteriole cells. Am. J. Physiol. 2011, 300, 335–346. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Kim, D.M.; Nimigean, C.M. Voltage-gated potassium channels: A structural examination of selectivity and gating. Cold Spring Harb. Perspect. Biol. 2016, 5, a029231. [Google Scholar] [CrossRef] [Green Version]
  10. Wulff, H.; Castle, N.A.; Pardo, L.A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov. 2009, 8, 982. [Google Scholar] [CrossRef] [PubMed]
  11. Zhao, W.; Chen, Y. Progress in research of Kv1.1 and Kv1.3 channels as therapeutic targets. Curr. Top. Med. Chem. 2016, 16, 1877–1885. [Google Scholar] [CrossRef]
  12. Patel, S.P.; Campbell, D.L. Transient outward potassium current, ‘Ito’, phenotypes in the mammalian left ventricle: Underlying molecular, cellular and biophysical mechanisms. J. physiol. 2005, 569, 7–39. [Google Scholar] [CrossRef] [PubMed]
  13. Marzian, S.; Stansfeld, P.J.; Rapedius, M.; Rinne, S.; Nematian-Ardestani, E.; Abbruzzese, J.L.; Steinmeyer, K.; Sansom, M.S.; Sanguinetti, M.C.; Baukrowitz, T.; et al. Side pockets provide the basis for a new mechanism of Kv channel-specific inhibition. Nat. Chem. Biol. 2013, 9, 507–513. [Google Scholar] [CrossRef] [Green Version]
  14. Long, S.B.; Campbell, E.B.; MacKinnon, R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005, 309, 897–903. [Google Scholar] [CrossRef] [Green Version]
  15. Chen, R.; Robinson, A.; Gordon, D.; Chung, S.H. Modeling the binding of three toxins to the voltage-gated potassium channel (Kv1.3). Biophys. J. 2011, 101, 2652–2660. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Khabiri, M.; Nikouee, A.; Cwiklik, L.; Grissmer, S.; Ettrich, R. Charybdotoxin unbinding from the mKv1.3 potassium channel: A combined computational and experimental study. J. Phys. Chem. B 2011, 115, 11490–11500. [Google Scholar] [CrossRef]
  17. Lee, J.H.; Lee, B.H.; Choi, S.H.; Yoon, I.S.; Pyo, M.K.; Shin, T.J.; Choi, W.S.; Lim, Y.; Rhim, H.; Won, K.H.; et al. Ginsenoside Rg3 inhibits human Kv1.4 channel currents by interacting with the Lys531 residue. Mol. Pharmacol. 2008, 73, 619–626. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Liu, H.; Danthi, S.J.; Enyeart, J.J. Curcumin potently blocks Kv1.4 potassium channels. Biochem. Biophys. Res. Commun. 2006, 344, 1161–1165. [Google Scholar] [CrossRef] [Green Version]
  19. Yeom, H.D.; Lee, J.H. Regulation of human Kv1.4 channel activity by the antidepressant metergoline. Biol. Pharm. Bull. 2016, 39, 1069–1072. [Google Scholar] [CrossRef]
  20. Binzen, U.; Greffrath, W.; Hennessy, S.; Bausen, M.; Saaler-Reinhardt, S.; Treede, R.D. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience 2006, 142, 527–539. [Google Scholar] [CrossRef]
  21. Rasmusson, R.L.; Morales, M.J.; Castellino, R.C.; Zhang, Y.; Campbell, D.L.; Strauss, H.C. C-type inactivation controls recovery in a fast inactivating cardiac K+ channel (Kv1.4) expressed in Xenopus oocytes. J. Physiol. 1995, 489, 709–721. [Google Scholar] [CrossRef] [Green Version]
  22. Xu, J.; Zhao, W.; Pan, L.; Zhang, A.; Chen, Q.; Xu, K.; Lu, H.; Chen, Y. Peimine, a main active ingredient of Fritillaria, exhibits anti-inflammatory and pain suppression properties at the cellular level. Fitoterapia 2016, 111, 1–6. [Google Scholar] [CrossRef] [PubMed]
  23. Waterhouse, A.; Bertoni, M.; Bienert, S.; Studer, G.; Tauriello, G.; Gumienny, R.; Heer, F.T.; de Beer, T.A.P.; Rempfer, C.; Bordoli, L.; et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018, 46, W296–W303. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Ren, Y.; Pan, L.; Zhao, W.; Xu, L.; Xu, J.; Lu, H.; Chen, Y. Neochamaejasmin A inhibits KV1.4 channel activity via direct binding to the pore. Brain Res. 2018, 1683, 17–26. [Google Scholar] [CrossRef]
  26. Huey, R.; Morris, G.M.; Olson, A.J.; Goodsell, D.S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 2007, 28, 1145–1152. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Concentration-dependent inhibition of KV1.2 channels. (A). Representative KV1.2 channel currents elicited by 2000 ms voltage steps up to +20 mV from a holding potential of −80 mV, in the absence and presence of different concentrations of 2-APB. (B). The time course of KV1.2 currents after 2-APB treatment. (C). Concentration response curve of KV1.2 currents inhibited by 2-APB. The percentage inhibitions against the 2-APB concentration were analyzed by the Hill equation. (D). I-V relationships of wild-type KV1.2 channels in the absence or presence of 2-APB. Voltage pulses 2000 ms in duration were applied from −50 mV to 80 mV with 10 mV increments each time, with a holding potential of −80 mV. The interval between pulses was 10 s. * represents p < 0.01.
Figure 1. Concentration-dependent inhibition of KV1.2 channels. (A). Representative KV1.2 channel currents elicited by 2000 ms voltage steps up to +20 mV from a holding potential of −80 mV, in the absence and presence of different concentrations of 2-APB. (B). The time course of KV1.2 currents after 2-APB treatment. (C). Concentration response curve of KV1.2 currents inhibited by 2-APB. The percentage inhibitions against the 2-APB concentration were analyzed by the Hill equation. (D). I-V relationships of wild-type KV1.2 channels in the absence or presence of 2-APB. Voltage pulses 2000 ms in duration were applied from −50 mV to 80 mV with 10 mV increments each time, with a holding potential of −80 mV. The interval between pulses was 10 s. * represents p < 0.01.
Molecules 28 00871 g001
Figure 2. Concentration-dependent inhibition of KV1.3 channels. (A). Representative KV1.3 channel currents elicited by 2000 ms voltage steps up to +40 mV from a holding potential of −80 mV, in the absence and presence of different concentrations of 2-APB. (B). The time course of KV1.3 currents treated with different 2-APB concentrations. (C). Concentration response curve of hKV1.3 currents inhibited by 2-APB. The percentage inhibitions against the 2-APB concentration were analyzed by the Hill equation. (D). I-V relationships of wild-type KV1.3 channels in the absence or presence of 2-APB. Voltage pulses 2000 ms in duration were applied in 10 mV increments and at 10 s intervals from a holding potential of −80 mV. * represents p < 0.01.
Figure 2. Concentration-dependent inhibition of KV1.3 channels. (A). Representative KV1.3 channel currents elicited by 2000 ms voltage steps up to +40 mV from a holding potential of −80 mV, in the absence and presence of different concentrations of 2-APB. (B). The time course of KV1.3 currents treated with different 2-APB concentrations. (C). Concentration response curve of hKV1.3 currents inhibited by 2-APB. The percentage inhibitions against the 2-APB concentration were analyzed by the Hill equation. (D). I-V relationships of wild-type KV1.3 channels in the absence or presence of 2-APB. Voltage pulses 2000 ms in duration were applied in 10 mV increments and at 10 s intervals from a holding potential of −80 mV. * represents p < 0.01.
Molecules 28 00871 g002
Figure 3. Concentration-dependent inhibition of KV1.4 channels. (A). Representative KV1.4 channel currents elicited by 500 ms voltage steps up to −10 mV from a holding potential of −80 mV, in the absence and presence of different concentrations of 2-APB. (B). The time course of hKV1.4 currents after 2-APB treatment. (C). Concentration response curve of KV1.4 currents inhibited by 2-APB. The percentage inhibition against the 2-APB concentration was analyzed by the Hill equation. (D). I-V relationships of wild-type KV1.4 channels in the absence or presence of 2-APB. Voltage pulses 500 ms in duration were applied in 10 mV increments and at 10 s intervals from a holding potential of −80 mV. * represents p < 0.01.
Figure 3. Concentration-dependent inhibition of KV1.4 channels. (A). Representative KV1.4 channel currents elicited by 500 ms voltage steps up to −10 mV from a holding potential of −80 mV, in the absence and presence of different concentrations of 2-APB. (B). The time course of hKV1.4 currents after 2-APB treatment. (C). Concentration response curve of KV1.4 currents inhibited by 2-APB. The percentage inhibition against the 2-APB concentration was analyzed by the Hill equation. (D). I-V relationships of wild-type KV1.4 channels in the absence or presence of 2-APB. Voltage pulses 500 ms in duration were applied in 10 mV increments and at 10 s intervals from a holding potential of −80 mV. * represents p < 0.01.
Molecules 28 00871 g003
Figure 4. Effects of 2-APB on the onset and recovery of KV1.4 channels. ○ represents data after 2-APB application. ■ represents data before 2-APB application. I1 and I2 are the peak current amplitudes of the prepulse and test pulse. (A). Top panel: protocol for studying the onset of inactivation. Bottom panel: protocol for studying the recovery of inactivation. “X” means various lengths of duration. (B). The recovery of wild-type KV1.4 channels in the absence or presence of 2-APB. The X-axis represents the length between the prepulse and the test pulse. (C). The onset of the fast inactivation of KV1.4 channels in the absence or presence of 2-APB. The prepulse length varies from 2 ms to 128 ms. Molecules 28 00871 i001 points to the current amplitudes facilitated at a 2 ms prepulse length. (D). The onset of the slow inactivation of KV1.4 channels in the absence or presence of 2-APB. The prepulse length varied from 32 ms to 1024 ms.
Figure 4. Effects of 2-APB on the onset and recovery of KV1.4 channels. ○ represents data after 2-APB application. ■ represents data before 2-APB application. I1 and I2 are the peak current amplitudes of the prepulse and test pulse. (A). Top panel: protocol for studying the onset of inactivation. Bottom panel: protocol for studying the recovery of inactivation. “X” means various lengths of duration. (B). The recovery of wild-type KV1.4 channels in the absence or presence of 2-APB. The X-axis represents the length between the prepulse and the test pulse. (C). The onset of the fast inactivation of KV1.4 channels in the absence or presence of 2-APB. The prepulse length varies from 2 ms to 128 ms. Molecules 28 00871 i001 points to the current amplitudes facilitated at a 2 ms prepulse length. (D). The onset of the slow inactivation of KV1.4 channels in the absence or presence of 2-APB. The prepulse length varied from 32 ms to 1024 ms.
Molecules 28 00871 g004
Figure 5. Effects of 2-APB (30 µM) at a 2 ms prepulse at the onset. (A). Example current traces with (Black) and without 2-APB (Red). (B). Enlarged example prepulse current traces with (Black) and without 2-APB (Red). (C). Averages of current amplitudes at different times were analyzed by the Boltzman equation. ○ represents data after 2-APB application. ■ represents data before 2-APB application. Current amplitudes were normalized to the maximal peak currents in prepulses without 2-APB. □ represents the normalized current amplitudes with 2-APB, which were normalized to the maximal peak currents in the prepulse with 2-APB. (D). Bar graphs show the half-current activation time (left), which is relative to that without 2-APB treatment, and slopes (right) with and without 2-APB. * represents p < 0.01.
Figure 5. Effects of 2-APB (30 µM) at a 2 ms prepulse at the onset. (A). Example current traces with (Black) and without 2-APB (Red). (B). Enlarged example prepulse current traces with (Black) and without 2-APB (Red). (C). Averages of current amplitudes at different times were analyzed by the Boltzman equation. ○ represents data after 2-APB application. ■ represents data before 2-APB application. Current amplitudes were normalized to the maximal peak currents in prepulses without 2-APB. □ represents the normalized current amplitudes with 2-APB, which were normalized to the maximal peak currents in the prepulse with 2-APB. (D). Bar graphs show the half-current activation time (left), which is relative to that without 2-APB treatment, and slopes (right) with and without 2-APB. * represents p < 0.01.
Molecules 28 00871 g005
Figure 6. Effects of 100 μM 2-APB on mutations of the KV1.4 channel. (A). Representative wild-type currents elicited in the absence and presence of 2-APB. (B). Representative V549A currents elicited in the absence and presence of 2-APB. (C). Representative T551A currents elicited in the absence and presence of 2-APB. (D). Representative A553V currents elicited in the absence and presence of 2-APB. (E). Representative L554A currents elicited in the absence and presence of 2-APB.
Figure 6. Effects of 100 μM 2-APB on mutations of the KV1.4 channel. (A). Representative wild-type currents elicited in the absence and presence of 2-APB. (B). Representative V549A currents elicited in the absence and presence of 2-APB. (C). Representative T551A currents elicited in the absence and presence of 2-APB. (D). Representative A553V currents elicited in the absence and presence of 2-APB. (E). Representative L554A currents elicited in the absence and presence of 2-APB.
Molecules 28 00871 g006
Figure 7. Effects of 2-APB on the N-terminal truncated mutation of KV1.4. (A). Representative N-terminal truncated mutation of KV1.4 channel currents elicited in the absence and presence of various concentrations of 2-APB. (B). The time course of 2-APB effects on the N-terminal truncated mutation of KV1.4 currents (100 μM). (C). Concentration response curve of the N-terminal truncated mutation of KV1.4 channel currents inhibited by 2-APB. The percentage inhibitions against the 2-APB concentration were analyzed by the Hill equation.
Figure 7. Effects of 2-APB on the N-terminal truncated mutation of KV1.4. (A). Representative N-terminal truncated mutation of KV1.4 channel currents elicited in the absence and presence of various concentrations of 2-APB. (B). The time course of 2-APB effects on the N-terminal truncated mutation of KV1.4 currents (100 μM). (C). Concentration response curve of the N-terminal truncated mutation of KV1.4 channel currents inhibited by 2-APB. The percentage inhibitions against the 2-APB concentration were analyzed by the Hill equation.
Molecules 28 00871 g007
Figure 8. The fast onset of the N-terminal truncated mutation of KV1.4. (A). The onset of the fast inactivation of the N-terminal truncated mutation of KV1.4 channels in the absence or presence of 2-APB. The prepulse length varied from 2 ms to 32 ms. The protocol was the same as that in Figure 4A. Current amplitudes are facilitated at a 2 ms prepulse length. (B). The bar graph shows the facilitation of both the N-terminal truncated KV1.4 and wild-type-KV1.4 with and without 2-APB at a 2 ms prepulse. ■ represents the data of wild-type KV1.4. ○ represents the data of N-terminal truncated KV1.4. * represents p < 0.05.
Figure 8. The fast onset of the N-terminal truncated mutation of KV1.4. (A). The onset of the fast inactivation of the N-terminal truncated mutation of KV1.4 channels in the absence or presence of 2-APB. The prepulse length varied from 2 ms to 32 ms. The protocol was the same as that in Figure 4A. Current amplitudes are facilitated at a 2 ms prepulse length. (B). The bar graph shows the facilitation of both the N-terminal truncated KV1.4 and wild-type-KV1.4 with and without 2-APB at a 2 ms prepulse. ■ represents the data of wild-type KV1.4. ○ represents the data of N-terminal truncated KV1.4. * represents p < 0.05.
Molecules 28 00871 g008
Figure 9. Effects of 2-APB at a 2 ms prepulse at the onset of the N-terminal truncated mutation of KV1.4. (A). Example current traces with (Black) and without 2-APB (Red). (B). Enlarged example prepulse current traces with (Black) and without 2-APB (Red). (C). Average current amplitude at different times analyzed by the Bolzman equation. ○ represents data after 2-APB application, and ● represents data before 2-APB application. Current amplitudes were normalized to the maximal peak currents in prepulses without 2-APB. □ represents the normalized current amplitudes with 2-APB, which were normalized to the maximal peak currents in a prepulse with 2-APB. (D). Bar graphs show the half-current activation time (left), relative to the one without 2-APB, and a slope (right) with and without 2-APB. * represents p < 0.05; “n.s.” means “not significant”.
Figure 9. Effects of 2-APB at a 2 ms prepulse at the onset of the N-terminal truncated mutation of KV1.4. (A). Example current traces with (Black) and without 2-APB (Red). (B). Enlarged example prepulse current traces with (Black) and without 2-APB (Red). (C). Average current amplitude at different times analyzed by the Bolzman equation. ○ represents data after 2-APB application, and ● represents data before 2-APB application. Current amplitudes were normalized to the maximal peak currents in prepulses without 2-APB. □ represents the normalized current amplitudes with 2-APB, which were normalized to the maximal peak currents in a prepulse with 2-APB. (D). Bar graphs show the half-current activation time (left), relative to the one without 2-APB, and a slope (right) with and without 2-APB. * represents p < 0.05; “n.s.” means “not significant”.
Molecules 28 00871 g009
Figure 10. Induced-fit docking model of 2-APB binding KV1.2. (A). Side (right) views of the docked ligands in complex with the KV1.2 model. (B). Stereoscopic view of 2-APB binding active sites of KV1.2. (C). Planar view of 2-APB binding active sites of KV1.2. “----” shows the hydrogen bond between 2-APB and T401.
Figure 10. Induced-fit docking model of 2-APB binding KV1.2. (A). Side (right) views of the docked ligands in complex with the KV1.2 model. (B). Stereoscopic view of 2-APB binding active sites of KV1.2. (C). Planar view of 2-APB binding active sites of KV1.2. “----” shows the hydrogen bond between 2-APB and T401.
Molecules 28 00871 g010
Figure 11. Induced-fit docking model of 2-APB binding KV1.3. Induced-fit docking model of 2-APB binding KV1.3. (A). Side (right) views of the docked ligands in complex with the KV1.3 model. (B). Stereoscopic view of 2-APB binding active sites of KV1.3. (C). Planar view of 2-APB binding active sites of KV1.3. “----” shows the hydrogen bond between 2-APB and A473.
Figure 11. Induced-fit docking model of 2-APB binding KV1.3. Induced-fit docking model of 2-APB binding KV1.3. (A). Side (right) views of the docked ligands in complex with the KV1.3 model. (B). Stereoscopic view of 2-APB binding active sites of KV1.3. (C). Planar view of 2-APB binding active sites of KV1.3. “----” shows the hydrogen bond between 2-APB and A473.
Molecules 28 00871 g011
Figure 12. Induced-fit docking model of 2-APB binding KV1.4. Induced-fit docking model of 2-APB binding KV1.4. (A). Side (right) views of the docked ligands in complex with the KV1.4 model. (B). Stereoscopic view of 2-APB binding active sites of KV1.4. (C). Planar view of 2-APB binding active sites of KV1.4. “----” shows the hydrogen bond between 2-APB and V549.
Figure 12. Induced-fit docking model of 2-APB binding KV1.4. Induced-fit docking model of 2-APB binding KV1.4. (A). Side (right) views of the docked ligands in complex with the KV1.4 model. (B). Stereoscopic view of 2-APB binding active sites of KV1.4. (C). Planar view of 2-APB binding active sites of KV1.4. “----” shows the hydrogen bond between 2-APB and V549.
Molecules 28 00871 g012
Table 1. Effects of 2-APB (100 μM) on mutation Kv1.4 channels expressed in CHO cells.
Table 1. Effects of 2-APB (100 μM) on mutation Kv1.4 channels expressed in CHO cells.
MutationsInhibition (%) S.E.MNumber of Cells
WT56.82.76
KV1.4_G548AN.D.N.D.N.D.
KV1.4_V549A44.1 *0.24
KV1.4_L550A50.04.44
KV1.4_T551A37.8 *6.04
KV1.4_I552AN.D.N.D.N.D.
KV1.4_A553V18.4 *7.06
KV1.4_L554A32.9 *9.74
KV1.4_P555AN.D.N.D.N.D.
KV1.4_V556A60.80.53
KV1.4_P557AN.D.N.D.N.D.
KV1.4_V558A57.34.15
KV1.4_I559AN.D.N.D.N.D.
KV1.4_V560AN.D.N.D.N.D.
KV1.4_S561AN.D.N.D.N.D.
KV1.4_ truncation23.1 *2.55
N.D., not determined. * p < 0.01 compared with the wild-type KV1.4 channel.
Table 2. Docking parameters of 2-APB binding three channels.
Table 2. Docking parameters of 2-APB binding three channels.
LigandProteinBinding Amino Acid ResiduesBinding Energy
(kcal/mol)
Inhibition Constant, Ki (μM)VDW_HB Desolv_Energy
(kcal/mol)
Ligand Efficiency
2-APBKv1.2 (2A79)T401−6.04218.87 −6.000.36
Kv1.3 (model)A473−5.56350.52 −6.560.30
Kv1.4 (model)V549−7.26118.52 −7.560.43
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhao, W.; Pan, L.; Stalin, A.; Xu, J.; Wu, L.; Ke, X.; Chen, Y. Inhibitory Effects of 2-Aminoethoxydiphenyl Borate (2-APB) on Three KV1 Channel Currents. Molecules 2023, 28, 871. https://doi.org/10.3390/molecules28020871

AMA Style

Zhao W, Pan L, Stalin A, Xu J, Wu L, Ke X, Chen Y. Inhibitory Effects of 2-Aminoethoxydiphenyl Borate (2-APB) on Three KV1 Channel Currents. Molecules. 2023; 28(2):871. https://doi.org/10.3390/molecules28020871

Chicago/Turabian Style

Zhao, Wei, Lanying Pan, Antony Stalin, Jianwei Xu, Liren Wu, Xianfu Ke, and Yuan Chen. 2023. "Inhibitory Effects of 2-Aminoethoxydiphenyl Borate (2-APB) on Three KV1 Channel Currents" Molecules 28, no. 2: 871. https://doi.org/10.3390/molecules28020871

Article Metrics

Back to TopTop